Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pregnancy-specific beta-1-glycoprotein 4 (PSG4)
- Target
- PSG4
- Molecular classification
- Immunoglobulin superfamily domain-containing protein, Carcinoembryonic antigen (CEA) family, specifically the PSG subgroup
01
Overview
Pregnancy-specific beta-1-glycoprotein 4 (PSG4) is a member of the carcinoembryonic antigen (CEA) gene family, belonging to the immunoglobulin superfamily and specifically the PSG subgroup. It is synthesized in large amounts by placental trophoblast cells and released into maternal circulation during pregnancy. PSG4 may have roles in modulating the innate immune response and mediating cell adhesion via integrin interaction, owing to its RGD motif. The gene is located on chromosome 19 within a cluster of related PSG genes. Several transcript variants and isoforms exist due to alternative splicing. PSG4 is not currently considered a receptor, enzyme, or other direct drug target. Instead, its medical relevance is primarily as a potential biomarker in pregnancy-related disorders and certain cancers, although further research is needed for definitive clinical utility
- Other names
- PSG4PSBG-4PSG9PSBG-9Pregnancy-specific glycoprotein 4Pregnancy-specific glycoprotein 9Pregnancy-specific beta-1-glycoprotein 9PS-beta-G-4PS-beta-G-9
02
Mechanism of action
Not applicable; no drugs target PSG4 directly.
03
Biological functions
Regulation of the innate immune systemCell surface interactions, especially at the vascular wallPlacental biology: produced by placental trophoblasts, entering maternal circulation during pregnancyMay act as an adhesion molecule via RGD motif, potentially mediating integrin interactions
04
Disease associations
Gestational ChoriocarcinomaRh IsoimmunizationDifferential expression signatures noted in cancers, though no direct involvement as a pathogenic factor is establishedPotential biomarker associations with pregnancy complications; clinical utility remains exploratory
05
Safety considerations
None direct for PSG4 as a therapeutic target; not known to be targeted by drugs.In terms of its use as a biomarker, the specificity of PSG4 is challenged by the overlapping expression and function of multiple PSG family members, which may limit diagnostic utility.
06
Biomarkers
PSG4 is investigated as a biomarker for pregnancy-related conditions and potentially other pathologies where its expression is altered (e.g. some gestational cancers and immunological conditions). Expression levels may serve as part of a panel of PSGs for diagnostic purposes, but clinical adoption is limited and not routine.
Beyond the preview
Go deeper on Pregnancy-specific beta-1-glycoprotein 4 (PSG4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pregnancy-specific beta-1-glycoprotein 4 (PSG4).